GM-CSF-based treatments in COVID-19: reconciling opposing therapeutic approaches

    Thumbnail
    Citations
    Scopus
    Web of Science
    Altmetric
    19
    16
    Author
    Lang, FM; Lee, KM-C; Teijaro, JR; Becher, B; Hamilton, JA
    Date
    2020-06-23
    Source Title
    Nature Reviews Immunology
    Publisher
    NATURE PUBLISHING GROUP
    University of Melbourne Author/s
    Lee, Kevin; Hamilton, John
    Affiliation
    Medicine and Radiology
    Metadata
    Show full item record
    Document Type
    Journal Article
    Citations
    Lang, F. M., Lee, K. M. -C., Teijaro, J. R., Becher, B. & Hamilton, J. A. (2020). GM-CSF-based treatments in COVID-19: reconciling opposing therapeutic approaches. NATURE REVIEWS IMMUNOLOGY, 20 (8), pp.507-514. https://doi.org/10.1038/s41577-020-0357-7.
    Access Status
    Access this item via the Open Access location
    URI
    http://hdl.handle.net/11343/254504
    DOI
    10.1038/s41577-020-0357-7
    Open Access URL
    https://europepmc.org/articles/PMC7309428?pdf=render
    Abstract
    Therapeutics against coronavirus disease 2019 (COVID-19) are urgently needed. Granulocyte-macrophage colony-stimulating factor (GM-CSF), a myelopoietic growth factor and pro-inflammatory cytokine, plays a critical role in alveolar macrophage homeostasis, lung inflammation and immunological disease. Both administration and inhibition of GM-CSF are currently being therapeutically tested in COVID-19 clinical trials. This Perspective discusses the pleiotropic biology of GM-CSF and the scientific merits behind these contrasting approaches.

    Export Reference in RIS Format     

    Collections